Resolution Therapeutics has extended its inflammatory and fibrotic disease pipeline with its in vivo regenerative macrophage therapy (RMT). 

The announcement comes with Resolution executing Material Transfer Agreements with independent, best-in-class lipid nanoparticle (LNP) technology providers. Under the agreements, Resolution will conduct systematic assessments of LNP formulations for the engineering of the myeloid compartment in vivo, with preliminary results expected later this year. 

Resolution claims its in vivo programme tests rigorously selected, differentiated LNP formulations in parallel, maximising the probability of identifying an optimal delivery vehicle while compressing development timelines.  

The biopharmaceutical company says the in vivo programme complements RTX001, Resolution’s autologous engineered programme and lead asset. The ongoing Phase I/II clinical study EMERALD is being conducted in patients with end-stage liver disease who have a history of decompensated liver cirrhosis, a patient population with the only treatment alternative being a liver transplant. 

By progressing RMT in two platforms, the company aims to broaden the patient population able to benefit from its innovative approach. 

“This programme marks a decisive inflection point for Resolution Therapeutics — an acceleration of ambition to match the urgent patient need,” said Amir Hefni, Chief Executive Officer of Resolution. 

“EMERALD, our autologous programme, is in the clinic with interim data expected later this year. We are building an in vivo platform to bring regenerative macrophage therapy to more patients.”